<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05113173</url>
  </required_header>
  <id_info>
    <org_study_id>YYYXYJ-2021-085</org_study_id>
    <nct_id>NCT05113173</nct_id>
  </id_info>
  <brief_title>Study on the Relationship Between Pathological Features of Achalasia and Prognosis of Per-oral Endoscopic Myotomy</brief_title>
  <official_title>Study on the Relationship Between Different Pathological Features of Achalasia and Prognosis of Per-oral Endoscopic Myotomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fandong Meng</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Achalasia is the most common motility disorder of esophagus, characterized by disorders of&#xD;
      the lower esophageal sphincter (LES). Normal peristalsis of the esophagus is eliminated and&#xD;
      replaced by synchronous or ineffective contraction. Based on high-resolution manometry (HRM),&#xD;
      the participants with achalasia were categorized into 3 subtypes, type I: achalasia with&#xD;
      minimum esophageal pressurization, type II: achalasia with esophageal compression and type&#xD;
      III: achalasia with spasm.&#xD;
&#xD;
      Previous studies have found that the pathological features of the esophageal muscular layers&#xD;
      in participants with achalasia are degeneration of nerve plexus, reduction of interstitial&#xD;
      cells of Cajal (ICCs) and infiltration of different inflammatory cells. Different subtypes of&#xD;
      achalasia have different pathological characteristics and esophageal motility. Now, per-oral&#xD;
      endoscopic myotomy (POEM) is a main therapy for participants with achalasia. Most studies&#xD;
      have focused on the relationship between pathological features and motility characteristics&#xD;
      of achalasia, but there are few studies on the relationship between pathological features and&#xD;
      therapeutic effect of POEM.&#xD;
&#xD;
      This study will prospectively collect data of participants undergoing POEM for achalasia in&#xD;
      Beijing Friendship Hospital, including demographic data, drug and surgical treatment data&#xD;
      during hospitalization. All participants are required to obtain esophageal muscle biopsy for&#xD;
      pathological examination during POEM. The participants will be followed up until 12 months&#xD;
      for improvement in clinical symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Achalasia is the most common motility disorder of esophagus, characterized by disorders of&#xD;
      the lower esophageal sphincter (LES). Normal peristalsis of the esophagus is eliminated and&#xD;
      replaced by synchronous or ineffective contraction. Based on high-resolution manometry (HRM),&#xD;
      the participants with achalasia were categorized into 3 subtypes, type I: achalasia with&#xD;
      minimum esophageal pressurization, type II: achalasia with esophageal compression and type&#xD;
      III: achalasia with spasm.&#xD;
&#xD;
      Previous studies have found that the pathological features of the esophageal muscular layers&#xD;
      in participants with achalasia are degeneration of nerve plexus, reduction of interstitial&#xD;
      cells of Cajal (ICCs) and infiltration of different inflammatory cells. Different subtypes of&#xD;
      achalasia have different clinical characteristics and esophageal motility. Studies have found&#xD;
      that ganglion cells in type I participants are significantly reduced compared with type II&#xD;
      participants, but the pattern is similar, which may indicate that type I achalasia represents&#xD;
      the progression of type II achalasia. In addition, Achalasia is related to viral infection&#xD;
      and autoimmune disease. Studies have shown that pathological biopsies of muscle in&#xD;
      participants with achalasia show significantly increased rates of lymphocytes in tissues, as&#xD;
      well as mast cells.&#xD;
&#xD;
      Now, per-oral endoscopic myotomy (POEM) is a main therapy for participants with achalasia.&#xD;
      Most studies have focused on the relationship between pathological features and motility&#xD;
      characteristics of achalasia, but there are few studies on the relationship between&#xD;
      pathological features and therapeutic effect of POEM.&#xD;
&#xD;
      This study will prospectively collect data of participants undergoing POEM for achalasia in&#xD;
      Beijing Friendship Hospital, including demographic data, drug and surgical treatment data&#xD;
      during hospitalization. All participants are required to obtain esophageal muscle biopsy for&#xD;
      pathological examination during POEM. The participants will be followed up until 12 months&#xD;
      for improvement in clinical symptoms and gastroesophageal reflux after POEM.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2021</start_date>
  <completion_date type="Anticipated">April 16, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 16, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Eckardt score</measure>
    <time_frame>12months after POEM</time_frame>
    <description>Eckardt score is used to assess the severity of symptoms in participants with achalasia. The Eckardt score evaluates weight loss, dysphagia, retrosternal pain, and reflux of achalasia. The maximum value is 12 and the minimum value is 0. Higher scores mean a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GERDQ score</measure>
    <time_frame>12months after POEM</time_frame>
    <description>GERDQ is a abbreviation of gastroesophageal reflux disease questionnaire. GERDQ score is used to assess the degree of gastroesophageal reflux after POEM. The maximum value is 18 and the minimum value is 0. Higher scores mean a worse outcome. Gastroesophageal reflux disease can be diagnosed if the GERDQ score is greater than or equal to 8.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Esophageal Achalasia</condition>
  <arm_group>
    <arm_group_label>Type I Achalasia</arm_group_label>
    <description>Severe loss of ganglion cells,loss of ICCs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type II Achalasia</arm_group_label>
    <description>Loss of ICCs, mild loss of ganglion cells.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type III Achalasia</arm_group_label>
    <description>Preserved ICCs, less loss of ganglion.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      esophageal muscular layers&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with achalasia are hospitalized in Beijing Friendship Hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants with achalasia&#xD;
&#xD;
          -  Age: 18 to 80 years&#xD;
&#xD;
          -  Accept for the treatment of POEM&#xD;
&#xD;
          -  Sign the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants under 18 years old&#xD;
&#xD;
          -  Previously received treatment of achalasia, Barrett's esophagus, esophageal stricture,&#xD;
             liver cirrhosis, and/or esophageal varices, tumors, allergic diseases and hiatal&#xD;
             hernia.&#xD;
&#xD;
          -  Use non-steroidal anti-inflammatory drugs, corticosteroids and other immunosuppressive&#xD;
             agents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fandong Meng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fandong Meng</last_name>
    <phone>+8613681061594</phone>
    <email>mfdzhaotianyu@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Junnan Gu</last_name>
    <phone>+8618611050395</phone>
    <email>gujunnan0916@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fandong Meng, Doctor</last_name>
      <phone>+86-10-63138650</phone>
      <email>mfdzhaotianyu@163.com</email>
    </contact>
    <investigator>
      <last_name>Junnan Gu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fandong Meng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Liu ZQ, Chen WF, Wang Y, Xu XY, Zeng YG, Lee Dillon D, Cheng J, Xu MD, Zhong YS, Zhang YQ, Yao LQ, Zhou PH, Li QL. Mast cell infiltration associated with loss of interstitial cells of Cajal and neuronal degeneration in achalasia. Neurogastroenterol Motil. 2019 May;31(5):e13565. doi: 10.1111/nmo.13565. Epub 2019 Mar 13.</citation>
    <PMID>30868687</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 11, 2021</study_first_submitted>
  <study_first_submitted_qc>October 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Fandong Meng</investigator_full_name>
    <investigator_title>chief physician</investigator_title>
  </responsible_party>
  <keyword>Esophageal Achalasia</keyword>
  <keyword>per-oral endoscopic myotomy</keyword>
  <keyword>pathology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Achalasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Investigators haven't decided which parts to share yet.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 1, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT05113173/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 1, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT05113173/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

